As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e.,aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
Lead Underwriter
Loop Capital Markets, LLC
Co-Managers
Brookline Capital Markets, a division of Arcadia Securities, LLC, Maxim Group, LLC
